Publications - Matoke Holdings, Reactive Oxygen Technology

1. Dryden M. Lockyer G. Kordo S. Cooke J. Engineered honey: in vitro antimicrobial activity of a novel topical wound care treatment. Journal of Global Antimicrobial Resistance 2014.

2. Dryden MS. Hudgell. Saeed K. Dryden AWS. Brooks J. Cooke J. Surgihoney – honey wound treatment: first report of in-vitro activity and early clinical evaluation. Federation of Infection Societies. Birmingham UK, 2013.

3. Dryden M. Goddard C. Madadi A. Heard M. Saeed K. Cooke J. Bioengineered Surgihoney as an antimicrobial wound dressing to prevent Caesarean wound infection: a clinical and cost-effectiveness study. British Journal of Midwifery 2014;22:23–7.

4. Dryden M. Tawse C. Adams J. Saeed K. Cooke J. The use of Surgihoney to prevent or eradicate bacterial colonisation in dressing oncology long vascular lines. Journal of Wound Care 2014;23:338-41.

5. Cooke J. When antibiotics can be avoided in skin inflammation and bacterial colonization: a review of topical treatments. Current Opinion in Infectious Diseases 2014;27:125-9.

6. Cooke J, Dryden M, Patton T, Brennan J, Barrett J. The antimicrobial activity of prototype modified honeys that generate reactive oxygen species (ROS) hydrogen peroxide. BMC research notes 2015;8:20.http://www.biomedcentral.com/1756-0500/8/20.

7. Halstead F. Oppenheim B. Dryden M. The in vitro antibacterial activity of engineered honey (Surgihoney®) against important biofilm-forming burn wound pathogens. Federation of Infection Societies. Harrogate, UK,2014.

8. Dryden M, Milward G, Saeed K. Infection prevention in wounds with Surgihoney. The Journal of hospital infection 2014;88:121-2.

9. Dunnill C, Patton T, Brennan J, et al. Reactive oxygen species (ROS) and wound healing: the functional role of ROS and emerging ROS-modulating technologies for augmentation of the healing process. Int Wound J 2015.

10. Khan W, Williams R, Metah A, Morgan-Jones R. Surgihoney as a novel antimicrobial coating in salvage revision total knee arthroplasty. Orthopaedic Proceedings 2015;97-B:66-.

11. Dryden M. Dickinson A. Brooks J. Hudgell L. Saeed L.. Cutting KF. A multi-centre clinical evaluation of Reactive Oxygen(tm) topical wound gel in 114 wounds. Journal of Wound Care 2016;25:140-6.

12. Halstead FD, Webber MA, Rauf M, Burt R, Dryden M, Oppenheim BA. In vitro activity of an engineered honey, medical-grade honeys, and antimicrobial wound dressings against biofilm-producing clinical bacterial isolates. J Wound Care 2016;25:93-102.

13. Dryden M. Saeed K. Dickinson A. Clarke J. Engineered honey to manage bacterial bioburden and biofilm in chronic wounds. European Wound Management Association London, 2015.

14. Halstead F. Oppenheim B. Dryden M. The in vitro antibacterial activity of engineered honey (Surgihoney™) against important biofilm-forming burn wound pathogens. 25th European Congress of Clinical Microbiology and Infectious Diseases. Copenhagen, Denmark, 2015.

15. Lipsky BA, Dryden M, Gottrup F, et al., Antimicrobial stewardship in wound care: a Position Paper from the British Society for Antimicrobial Chemotherapy and European Wound Management Association J. Antimicrob. Chemother. 2016, 10.1093/jac/dkw287

16. Matthew Dryden , Jonathan Cooke Rami Salib, Rebecca Holding, Sylvia Pender, Jill Brooks. Hot Topics in Reactive Oxygen therapy: antimicrobial and immunological mechanisms, safety, and clinical applications. J Glob Antib Res. 2017 Feb 17. pii: S2213-7165(17)30024-3. doi: 10.1016/j.jgar.2016.12.012. [Epub ahead of print] Review.

17. Matthew S Dryden, Jonathan Cooke, Rami J Salib, Rebecca Holding, Timothy Biggs, Ali A Salamat, Raymond N Allan, Rachel S. Newby, Fenella Halstead, Beryl Oppenheim, Thomas Hall, Sophie C. Cox, Liam M. Grover , Zain Al-hindi, Lilyann Novak-Frazer , Malcolm D. Richardson. Reactive Oxygen: a novel antimicrobial mechanism for targeting biofilm-associated infection. J Glob Antib Res. 2017 Feb 14;8:186-191. doi: 10.1016/j.jgar.2016.12.006. [Epub ahead of print] Review.

18. MS Dryden. Reactive Oxygen therapy: a novel therapy in soft tissue infection. Current Opinion in Infectious Disease 2017 Apr; 30(2):143-149. doi:10.1097/QCO.0000000000000350.

19. Dryden M Reactive oxygen species treatment in the management of wounds. Wounds UK 2017 Vol 13 No 2 26-33.

20. Dryden M, Reactive oxygen therapy: a novel antimicrobial, International Journal of Antimicrobial Agents (2017), http://dx.doi.org/doi:10.1016/j.ijantimicag.2017.08.029.

Significant historical advances in wound management

1. The introduction of the halogen, iodine, to control wound infection during the American Civil War (1861-1865).

2. The recognition of the need to create an aseptic wound environment, led by Johnson and Johnson. Inspired by a speech by antiseptic advocate Joseph Lister, Robert Wood Johnson and his brothers created a line of ready-to-use surgical dressings in 1885.

3. The introduction of the heavy metal, silver, to control battlefield wound infections in the First World War. Subsequently, other heavy metals, like mercury have been used but are now seen as just too toxic.

4. The development of antibiotics, accelerated by the Second World War dramatically improved the life expectancy of injured personnel, particularly those with systemic infections. However, they had limited ability to deal with topical wound infections since they don’t reach the site of the infection, the wound bed, and the sub-optimal doses reaching the wound actively stimulate bacterial resistance. The widespread use of broad spectrum antibiotics as a front line treatment for military personnel suffering traumatic injuries has selected multiply resistant strains, resulting in a formerly harmless bacterial species such as Acinetobacter being placed on the WHO crisis list.

5. In the 1960’s research conducted by Dr George Winter, led to the realisation that keeping a wound base moist was key to effective healing, as opposed to the conventional wisdom of drying a wound. Virtually all modern dressings, no matter what technology they use and how they are marketed, essentially control wound moisture.

The evolution of Acinetobacter baumanii from harmless soil borne bacterium to WHO critical pathogen

Acinetobacter baumanii is a Gram-negative bacterium found in soil, where it plays an important role in the breakdown of organic chemical compounds to release nutrients in soluble inorganic forms that can be absorbed by plants. Acinetobacter species are found widely in nature and thrive in a broad range of temperatures and hence environments.

Acinetobacter is a key source of infection in immune compromised patients in hospital where it is associated with bacteremia, urinary tract infections, meningitis, infective endocarditis, and wound and burn infections. It is often associated with hospital-acquired pneumonia and has also been reported to infect skin and soft tissue in traumatic injuries and postsurgical wounds.

It is known colloquially as ‘Iraqibacter’ because of its presence in soft tissue infections experienced by soldiers returning from Iraq and Afghanistan. Furthermore, the use of broad spectrum antibiotics on the battleground has led to a rapid growth in resistance, leading the World Health Organisation in 2017 to name multidrug-resistant A. baumannii as one of its top three threats.

This has the potential to become a serious problem in military and veterans hospitals, where soldiers returning from active duty worldwide are treated in the same environment as other patients, however, the development of resistance is a global issue not just a problem for the military.